Why TG Therapeutics Is Tumbling 15% Today
After TG Therapeutics, Inc.'s(NASDAQ: TGTX) discussion with the FDA regarding its most advanced clinical-stage drug raised concerns over a speedy approval, shares in the company are losing 15% of their value as of 2 pm EDT.
TG Therapeutics reported earlier this year that adding its TG-1101, or ublituximab, to AbbVie Inc.'s (NYSE: ABBV) and Johnson & Johnson's (NYSE: JNJ) top-selling Imbruvica resulted in an objective response rate (ORR) of 78% in patients with high-risk chronic lymphocytic leukemia. The complete response rate to the two-drug combination was 7%. These results matched up favorably to the 45% ORR and 0% complete response rates for Imbruvica on its own.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Johnson & Johnson Aktie
226,70 €
1,09 %
Die Johnson & Johnson Aktie genießt uneingeschränkte Beliebtheit: Nur Buy-Einschätzungen.
Das Community-Kursziel von 228 € für Johnson & Johnson wurde mit dem aktuellen Kurs von 226.7 € realisiert.
